Revenue
2022
2023
2024
2025
Taysha Gene Therapies, Inc. (TSHA)
Price—Loading quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $9.8M | $8.3M | $15.5M | $2.5M | — | — |
| Research & development | $86.4M | $66.0M | $56.8M | $91.2M | $131.9M | $31.9M |
| Operating expenses | $120.3M | $99.8M | $87.9M | $164.9M | $173.3M | $43.0M |
| Operating income | −$110.5M | −$91.5M | −$72.4M | −$162.4M | −$173.3M | −$43.0M |
| Net income | −$109.0M | −$89.3M | −$111.6M | −$166.0M | −$174.5M | −$60.0M |
| Basic EPSper diluted share | -$0.34 | -$0.36 | -$0.96 | -$3.78 | -$4.64 | -$3.40 |
| Diluted EPSper diluted share | -$0.34 | -$0.36 | -$0.96 | -$3.78 | -$4.64 | -$3.40 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Apr 10, 2026Form 4 · 10b5-1 | Nagendran SukumarPresident and Head of R&D | SellCommon Stock | 200.0K | $4.46 | $892.0K | 1.14M |
| Feb 4, 2026Form 4 | Alam KamranCHIEF FINANCIAL OFFICER | SellCommon Stock | 1.7K | $4.52 | $7.5K | 1.44M |
| Jan 26, 2026Form 4 | Alam KamranCHIEF FINANCIAL OFFICER | SellCommon Stock | 23.8K | $4.61 | $109.9K | 1.44M |
| Jan 26, 2026Form 4 | Nagendran SukumarPresident and Head of R&D | SellCommon Stock | 26.9K | $4.61 | $124.1K | 1.32M |
| Jan 26, 2026Form 4 | Nolan Sean P.Chief Executive Officer | SellCommon Stock | 41.3K | $4.61 | $190.4K | 2.91M |